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Abstract
Systemic inflammatory response syndrome is an increased inflammatory state affecting the whole body. Mechanical
circulatory support (MCS) is a temporary or permanent form of extracorporeal support that may have an associated
complication of an exacerbated inflammatory response to the extracorporeal circuit. This brief review will focus on
understanding the complex pathophysiology of inflammatory response to MCS, factors that influence the extent of the
inflammatory response, the inflammatory response and outcomes as well as potential therapeutic strategies.
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Introduction
Systemic inflammatory response syndrome (SIRS) is an
exacerbated response of the human body to harmful stressors
like infections, pancreatitis, burns, surgery, trauma, ischemia,
reperfusion, or the presence of mechanical circulatory support
devices (MCS) as well as others.1 The current SIRS criteria
are based on changes in body temperature, heart rate,
respiratory rate, and white blood cell count.2 MCS devices can
provide circulatory support for patients with acute
hemodynamic compromise as well as chronic end-stage heart
failure, acute respiratory failure, or chronic respiratory failure
as a bridge to lung transplantation.3 These devices include
veno-arterial (V-A) and veno-venous (V-V) extracorporeal
membrane oxygenation (ECMO), percutaneous right
ventricular assist device (pRVAD) as well as percutaneous
temporary left ventricular assist devices (pLVAD), intraaortic balloon pump (IABP), left ventricular assist devices
(LVAD) and total artificial heart (TAH).

Pathophysiology of the Inflammatory Response to
Mechanical Circulatory Support Devices
Extracorporeal Membrane Oxygenation
The pathophysiology of inflammation during ECMO is
extremely complex and not fully understood. The
commencement of extracorporeal life support is associated
with an instantaneous inflammatory response similar to
systemic inflammatory response syndrome secondary to
contact between a patient’s blood and the foreign surfaces of
the ECMO circuit. The levels of proinflammatory cytokines
and complement levels increase rapidly, which results in
leukocyte activation.4 If the inflammatory response is severe
and persistent without any compensatory anti-inflammatory
response,5 it may lead to endothelial injury and end-organ
failure.
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The factors implicated in the complex immune and
inflammatory response to ECMO include:
• The contact system—factor XII, factor XI,
prekallikrein
and
high-molecular-weight
kininogen. The activation of these factors leads to
formation of kallikrein and bradykinin, which in
turn will promote coagulation and inflammation.4
• Intrinsic coagulation is triggered by the contact
system, and extrinsic coagulation is activated as
well to a lesser degree, promoting subsequent clot
formation.4
• Platelet activation—has two critically important
roles, the first one in hemostasis and the second
one in triggering inflammation through the release
of their granular content.4
• The complement system plays a critical role in the
innate immune response. While its response to
cardiopulmonary bypass has been described
earlier in the literature,6 the interaction between
complement activation and ECMO requires
additional investigations.
• Endothelial cell activation is another key element
in the inflammatory response during ECMO. The
inflammatory mediators triggered in response to
ECMO, lead to activation of the endothelial cells,
which further exacerbates the inflammatory
response by producing proinflammatory cytokines
and increases the expression of adhesion
molecules, leading to the increased migration of
leukocytes.4
• Furthermore, neutrophils are also activated by the
extracorporeal circuit. Upon neutrophil activation,
the cells degranulate, releasing cytotoxic
enzymes, which further exacerbate the
inflammation leading to end-organ damage.7
• Cytokines play an important role in the innate
immune response. Upon ECMO initiation,
proinflammatory, as well as anti-inflammatory
cytokines, are produced. The most studied
cytokines in relationship to ECMO are TNF-α, IL6, IL-8, and IL-10.4 Their precise roles require
further investigations.

Indications versus Contraindications for ECMO
Recommended indications for the use of ECMO include
refractory hypoxemia, use of mechanical ventilation for <7
days, risk of death greater than 50%, severe air leak syndrome,
and a diagnosis of severe myocarditis or cardiogenic shock.4
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Absolute
contraindications
include
significant
comorbidities from which a patient cannot recover. These
include severe immunosuppression, sepsis with bacteremia,
contraindications to systemic anticoagulation, severe multiple
organ failure, severe aortic dissection, acute intracerebral
hemorrhage, irreversible severe brain injury, critical
congenital heart defects, chronic lung disease, and lethal
chromosomal anomalies.4 Relative contraindications also
include an age of 65 years or older, a body mass index greater
than 30, prolonged ventilatory support, frailty,
allosensitization with prolonged waitlist time, and limitations
in vascular access.4 During the early phase of the COVID-19
pandemic, the Extracorporeal Life Support Organization
recommended prioritizing young, previously healthy patients
with only a single organ failure for ECMO support, as they
may derive the maximum benefit.5 As clinical experience
continued to evolve, these priorities were relaxed based on
program experience and increased access to health care
resources.

The Inflammatory Response to Ventricular Assist
Devices
Heart failure patients with reduced ejection fraction have
a baseline proinflammatory state secondary to myocardial
infarction, cardiogenic shock, or acute or chronic systolic
heart failure.
The mechanism through which VAD impacts
inflammation remains to be fully understood. The two key
elements involved in the body’s immune response are high
levels of shear stress and the contact of blood with foreign
materials.8 Leukocytes and platelets are continuously exposed
to high shear stress resulting in their activation.9 Published
data shows that neutrophils exposed to wall shear stress
greater than 25 dyne/cm2, lead to structural disruption.10
Moreover, the contact of leukocytes with foreign bodies leads
to protein absorption, creating either an inert surface or a
highly dynamic matrix, which can further promote cellular
activation and adhesion.11

Factors that Influence the Inflammatory Response
The factors that influence the extent of the inflammatory
response include the etiology of shock, the patient’s clinical
status (the degree of shock), the hemocompatibility as well as
the performance of the mechanical circulatory device applied
(ECMO, percutaneous LVAD or RVAD, surgically implanted
VAD). Another critical factor that can influence the
inflammatory response includes the trauma and potential
complications associated with the device insertion.

The Inflammatory Response and Outcomes
Diakos et al. retrospectively analyzed the neutrophil-tolymphocyte ratio (NRL) among 111 patients with cardiogenic
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shock supported by V-A ECMO or pLVAD/pRVAD and
found that compared to nonsurvivors, the survivors had a
lower NLR (7.4 ± 0.9 vs 14.4 ± 11; P < .001). Setiadi et al.
investigated Oncostatin M (OSM), a member of the IL-6
family of cytokines, as a potential biomarker to predict
outcomes in 30 patients with ARDS requiring V-V ECMO
support (manuscript in progress). Preliminary data showed
that the percentage of pre-ECMO decannulation plasma OSM
levels as compared to pre-ECMO cannulation levels was
significantly lower in the recovered patients compared to
expired patients.
Furthermore, OSM was also used as a potential
biomarker to predict infections in patients with LVADs. A
study that included 41 patients showed that elevated plasma
OSM pre-LVAD implantation was associated with an
increased risk of developing infections postimplantation as
compared to the control.12

Potential Therapeutic Strategies
At this point, there is no proven therapy to mitigate an
exacerbated inflammatory response. Most strategies are
currently experimental and primarily target cardiopulmonary
bypass. Therapies that were or are under investigation include
steroids, statins, protease inhibitors, milrinone, monoclonal
antibodies, mesenchymal stromal cells (animal model only),
and extracorporeal cytokine absorber therapy. An interesting
method is the potential removal of inflammatory factors by
extracorporeal methods. In a study by Gruda et al.,
hemoadsorption through porous polymer bead devices
reduced the levels of a broad spectrum of cytokines, pathogenassociated molecular patterns, damage-associated molecular
patterns, and mycotoxins by more than 50%.13

Summary
The pathophysiology of the inflammatory response to
MCS is extremely complex and requires further studies to
better understand the interaction between the two key
components: the host and the extracorporeal support. Using
MCS in patients with a certain degree of inflammation or
systemic inflammatory response syndrome adds to the
complexity and requires additional research to better
understand the patient and device interaction and to help
advance the technology as well as potential therapeutics.
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How do These Concepts Impact Clinical Practice?
By better understanding the complex pathophysiology of
the inflammatory response to MCS, we can help to develop
therapeutics, improve the current forms of extracorporeal
circulatory support to minimize an exacerbated immune
inflammatory response to the foreign circuits and pumps,
discover inflammatory markers to help predict outcomes, and
eventually provide better and safer patient care.
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